Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables: 2013-2025

Historic Receivables for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $147.3 million.

  • Amphastar Pharmaceuticals' Receivables rose 5.19% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.1 million, marking a year-over-year increase of 7.05%. This contributed to the annual value of $136.5 million for FY2024, which is 18.74% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Receivables of $147.3 million as of Q3 2025, which was up 10.36% from $133.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Receivables' 5-year high stood at $147.3 million during Q3 2025, with a 5-year trough of $67.9 million in Q2 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Receivables value was $133.5 million (recorded in 2025), while the average stood at $128.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Receivables declined by 6.12% in 2022 and then spiked by 53.93% in 2023.
  • Amphastar Pharmaceuticals' Receivables (Quarterly) stood at $78.8 million in 2021, then increased by 13.20% to $89.2 million in 2022, then climbed by 28.85% to $114.9 million in 2023, then grew by 18.74% to $136.5 million in 2024, then climbed by 5.19% to $147.3 million in 2025.
  • Its Receivables was $147.3 million in Q3 2025, compared to $133.5 million in Q2 2025 and $144.8 million in Q1 2025.